CHMX NEXT ChemX Corporation (PK)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2024

 

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to _____________

 

Commission File Number: 000-56379

 

NEXT-ChemX Corporation

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada		32-0446353
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

1980 Festival Plaza Drive, Summerlin South, Suite 300,

Las Vegas, Nevada 89135

(Address of principal executive offices, Zip Code)

 

(725) 867-0789

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

	Large accelerated filer ☐	Accelerated filer ☐
	Non-accelerated filer ☒	Smaller reporting company ☒
		Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares outstanding of each of the issuer’s classes of common stock, as of November 18, 2024 is as follows:

 

Class of Securities		Shares Outstanding
Common Stock, $0.001 par value		28,546,834

 

 

 

NEXT-ChemX Corporation

 

 

Quarterly Report on Form 10-Q

For the Quarter Ended September 30, 2024

 

TABLE OF CONTENTS

 

PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements	F-3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	5
Item 4.	Controls and Procedures	6
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	7
Item 1A.	Risk Factors	7
Item 2.	Unregistered Sale of Equity Securities and Use of Proceeds	7
Item 3.	Defaults Upon Senior Securities	7
Item 4.	Mine Safety Disclosures	7
Item 5.	Other Information	7
Item 6.	Exhibits	8
Signatures		9

 

 

NEXT-CHEMX CORPORATION

INTERIM FINANCIAL STATEMENTS

(UNAUDITED)

 

Table of Contents

 

	Page
Condensed balance sheets at March 31, 2024 and December 31, 2023	F-3
Condensed Statements of Operations for the three months ended March 31, 2024 and 2023	F-4
Condensed Statements of Changes in Stockholders’ Equity (Deficit) for the three months ended March 31, 2024 and 2023	F-5
Condensed Statements of Cash Flows for the three months ended March 31, 2024 and 2023	F-6
Notes to Unaudited Condensed Financial Statements	F-7

 

 

PART I

FINANCIAL INFORMATION

 

Important Notice: Deficient Report

 

The financial statements that form part of the present Quarterly Report on Form 10-Q for the period covering the third quarter of 2024 (the “2024 10-Q”) have not been reviewed by a registered public accounting firm. This filing must therefore be considered as substantially deficient. On May 3, 2024, the Company was made aware that its auditor, BF Borgers CPA PC, had been denied the privilege of appearing or practicing before the Securities and Exchange Commission (the “SEC”) as an accountant. The Company has appointed a new registered public accounting firm: Fruci & Associates II PLLC, Certified Public Accountants based in Spokane, Washington (“Fruci & Associates”) to replace BF Borgers. However, due to a vastly increased workload as well as the necessity of reauditing the 2023 Annual Report filed on Form 10-K (the “2023 10-K”), Fruci & Associates has been unable to complete the review of either the present 2024 10-Q or the previous 10-Q filed for the first and second quarters of 2024 on July 15, 2024 and August 19, 2024 respectively, as required. The present deficiency is entirely due to circumstances beyond the control of the Company.

 

The Company has been working diligently with Fruci & Associates to complete first 2023 10-K reaudit and has received initial notice that the audit is nearing completion. In connection with this review, the Company has been put on notice by the Auditor that they are reviewing the amortization policy used by the Company to date on its Intangible Asset. Company management considers this asset to be intangible and indefinite since the value of the intellectual property is not based on a patent with a finite life but rather on the technical knowhow supported by certain patents, moreover, the fundamental basis for the Company’s extraction technology is based on a radically different technology that has applications in many areas providing at present an undefined number of application fields and giving rise, potentially, to a number of specific patents in each of these fields as the general principal is adapted for specific use. As a result, the Company has not seen fit to consider the technology to have a finite value at the present time. Reference is made to the section relating to the evaluation of the technology below. In the event that the Auditor takes a different view of the value of the technology, it is unlikely that Management would oppose this view, and in the worst case, this may lead to a restatement of the value of the technology by reapplying amortization that was originally suspended on September 30, 2021. The result of this may lead to a serious reduction in the balance sheet value of the technology.

 

Notwithstanding the above possible restatement of the value of the technology of the Company due to the application of amortization, the Company has no reason to believe that either this present 2024 10-Q or any of the previously issued financial statements cannot be relied upon because of an error in the statements. The Company has appointed and continues to work with Fruci & Associates to carry out the audit and reviews and will make every effort to support Fruci & Associates in reauditing the 2023 10-K and refiling the previous 10-Q filing for the first quarter of 2024 and this present 2024 10-Q for the second quarter following the required reviews as soon as possible.

 

 

ITEM 1. FINANCIAL STATEMENTS.

 

NEXT-ChemX Corporation

Condensed Balance Sheets

(Unaudited)

(Not Reviewed)

 

		not reviewed September 30,				not reviewed December 31,
		2024				2023
ASSETS
Current Assets:
Cash		$	35,386			$	2,458
Financial Assets			68,229				64,944
Prepaid expense and other current assets			591,070				72,925
Total Current Assets			694,685				140,327
Property and equipment, net			8,619				12,621
Intangible asset, net			3,150,114				3,150,114
Total Non-current Assets			3,158,733				3,162,735
Total Assets		$	3,853,418			$	3,303,062
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities:
Accounts payable and accrued liabilities		$	3,020,703			$	2,443,207
Other Current Liabilities			511,980				511,980
Loan payable			845,000				945,000
Due to related party			104,445				32,238
Other Current Liabilities			104,445				32,238
Total Current Liabilities			4,482,128				3,932,425
Non-Current Liabilities:
Notes payable			1,220,004				-
Total Non-Current Liabilities			1,220,004				-
Total Liabilities		$	5,702,132			$	3,932,425
Stockholders’ Equity (Deficit):
Preferred stock, $0.001 par value, 5,000,000 shares authorized; 20,000 Series A Preferred stock issued and outstanding as of September 30, 2024			20				-
20,000 Series F Preferred stock issued and outstanding as of September 30, 2024			20				-
Preferred stock, value			20				-
Common stock, $0.001 par value, 100,000,000 shares authorized; 28,546,834 issued and outstanding			28,547				28,547
Additional paid-in capital			5,396,053				5,396,053
Accumulated deficit			(7,273,354	)			(6,053,963
Total Stockholders’ Equity (Deficit)			(1,848,714	)			(629,363	)
Total Liabilities and Stockholders’ Equity (Deficit)		$	3,853,418			$	3,303,062

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 

NEXT-ChemX Corporation

Condensed Statements of Operations

(Unaudited)

(Not Reviewed)

 

		not reviewed 2024				not reviewed 2023				not reviewed 2024				not reviewed 2023
		For the three months ended								For the nine months ended
		September 30,								September 30,
		not reviewed 2024				not reviewed 2023				not reviewed 2024				not reviewed 2023
Revenues			-				-				-				-
Operating expenses
General and administrative			319,441				403,435				1,163,868				1,421,663
Total operating expenses			319,441				403,435				1,163,868				1,421,663
Income (loss) from operations			(319,441	)			(403,435	)			(1,163,868	)			(1,421,663	)
Other income (expense)
Other income (expense)			14,401				(500,000	)			72,828				(296,947	)
Interest expense			(49,455	)			(19,422	)			(128,351	)			(59,944	)
Net other Income (expense)			(35,054	)			(519,422	)			(55,523	)			(356,891	)
Net income (loss)			(354,495	)			(922,857	)			(1,219,391	)			(1,778,554	)
Net income (loss) per common share: Basic and diluted			(0.01	)			(0.03	)			(0.04	)			(0.06	)
Weighted average number of common shares outstanding: Basic and diluted			28,546,834				28,495,747				28,546,834				28,439,508

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 

NEXT-ChemX Corporation

Condensed Statement of Changes in Stockholders’ Equity (Deficit)

(Unaudited)

(Not Reviewed)

 

For the Three, Six and Nine Months Ended September 30, 2024

 

		Shares				Amount				Shares				Amount				Capital				Deficit				Deficit
		Preferred Stocks								Common Stock								Additional Paid-in				Accumulated				Stockholders’
		Shares				Amount				Shares				Amount				Capital				Deficit				Deficit
Balance December 31, 2023			-				-				28,546,834			$	28,547			$	5,396,053			$	(6,053,963	)		$	(629,363	)
Net loss			-				-				-				-				-				(518,963	)			(518,963	)
Balance March 31, 2024			-				-				28,546,834				28,547				5,396,053				(6,572,926	)			(1,148,326	)
Issuance of Series A Preferred Stocks			20,000			$	20																				20
Net loss											-				-				-				(345,933	)			(345,933	)
Balance June 30, 2024			20,000			$	20				28,546,834			$	28,547			$	5,396,053			$	(6,918,859	)		$	(1,494,239	)
Issuance of Series F Preferred Stocks			20,000			$	20																				20
Issuance of Preferred Stocks			20,000			$	20																				20
Net loss			-				-				-				-				-				(354,495	)			(354,495	)
Balance Sept 30, 2024			40,000			$	40				28,546,834			$	28,547			$	5,396,053			$	(7,273,354	)		$	(1,848,714	)

 

For the three, six and nine months ended September 30, 2023

 

		Shares				Amount				Capital				Deficit				Deficit
		Common Stock								Additional Paid-in				Accumulated				Stockholders’
		Shares				Amount				Capital				Deficit				Deficit
Balance December 31, 2022	-		28,346,834			$	28,347			$	4,396,253			$	(3,692,732	)		$	731,868
Stock Issuances to 3rd Party			100,000				100				499,900								500,000
Net loss	-		-				-				-				(457,973	)			(457,973	)
Balance March 31, 2023	-		28,446,834				28,447				4,896,153				(4,150,705	)			773,895
Net Loss	-		-				-				-				(397,724	)			(397,724	)
Balance June 30, 2023	-		28,446,834			$	28,447			$	4,896,153			$	(4,548,428	)		$	376,171
Balance	-		28,446,834			$	28,447			$	4,896,153			$	(4,548,428	)		$	376,171
Stock Issuances to 3rd Party	-		100,000				100				499,900								500,000
Net loss	-		-				-				-				(922,857	)			(922,857	)
Balance September 30, 2023	-		28,546,834			$	28,547			$	5,396,053			$	(5,471,286	)		$	(46,686	)
Balance	-		28,546,834			$	28,547			$	5,396,053			$	(5,471,286	)		$	(46,686	)

 

The accompanying notes are an integral part of these consolidated financial statements

 

 

NEXT-ChemX Corporation

Condensed Statements of Cash Flows

(Unaudited)

(Not Reviewed)

 

		2024 not reviewed				2023 not reviewed
		For the nine months ended
		September 30,
		2024 not reviewed				2023 not reviewed
CASH FLOWS FROM OPERATING ACTIVITIES
Net income(loss)		$	(1,219,391	)		$	(1,778,554	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			4,002				4,002
Other income received in form Shares of Stocks			-				(203,050	)
Other Expense paid in stocks							500,000
Consultant commission paid in third party stock							101,525
Unrealized gain on trading securities			(3,285	)			-
Changes in Operating Assets and Liabilities:
Related Party Advances			72,247
Prepaid expenses and other assets			(518,145	)			(50,760	)
Accounts payable and accrued liabilities			631,500				1,060,379
Net cash provided by (used in) operating activities			(1,033,072	)			(366,458	)
INVESTING ACTIVITIES
Purchase of property and equipment			-				-
Net cash provided by (used in) investing activities			-				-
FINANCING ACTIVITIES
Proceeds from the Stock Issuance of Common Stocks			-				500,000
Proceeds from convertible notes payable			-				345,000
Net proceeds from convertible notes payable			1,046,000
Net proceeds from loan payable			20,000				-
Repayment of notes payable			-				(446,007	)
Net cash provided by (used in) financing activities			1,066,000				398,993
Net increase (decrease) in cash			32,928				32,535
Cash, beginning of year			2,458				28,355
Cash, end of the period		$	35,386			$	60,890
SUPPLEMENTAL DISCLOSURES:
Cash paid during the period for:
Income tax		$	-			$	-
Interest		$	-			$	37,212
NON-CASH INVESTING AND FINANCING ACTIVITIES
Conversion of loan, interest and debt to convertible note		$	174,004			$	-
Issuance of Preferred Stocks against Indebtedness		$	40			$	-

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 

NEXT-ChemX Corporation

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2024

not reviewed

 

NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS

 

Organization and Description of Business

 

NEXT-ChemX Corporation, formerly known as AllyMe Group Inc. (the “Company”, “we” or “us”) was incorporated under the laws of the State of Nevada on August 13, 2014, and has adopted a December 31 fiscal year end. The Company trades on the OTC market (Pink Sheet) under the symbol “CHMX”. On December 23, 2021, the Company filed SEC Form 8 A12G becoming a mandatory filer and has since complied with all reporting requirements of the Securities Exchange Commission as a reporting issuer.

 

Since April 2021, following a complete change of the Company’s shareholders, management, assets and strategy, the business of the Company became the commercialization of a novel innovative Ion-Targeting Continuous-Flow Direct Extraction Technology (“iTDE Technology”) as further described in Note 5 below. The iTDE Technology is embodied in certain patents and patent applications as well as proprietary knowledge.

 

The primary focus of the Company is the commercial launch of its iTDE Technology in a scalable system and cost-effective system that may be deployed remotely to customer locations. The Company’s technology, when fully tested and implemented, is expected to enable the commercial extraction of lithium from natural brines and geothermal sources as well as liquors from leached mined ore solutions. In addition, since the first quarter of 2024, management began to focus on developing two or three other targeted systems for the mining of metals as well as water treatment systems and recycling.

 

Potential future commercial applications for the iTDE Technology include, but are not limited to:

 

	●	Extracting Fatty Acids from Vegetable Oils for More Economical Refining;
	●	Extracting of Radioactive Ions from Nuclear Plant Stored Water;
	●	Extracting of Metal Ions from Mine Leach Solutions, Effluent, or Tailings; and
	●	Desalination of Sea Water, by Extracting Ions for Water Purification

 

During the first nine months of 2024, the Company has continued to manage the construction of the first of two pilot plant systems that will form the basis of its ongoing commercialization efforts by demonstrating the scalability of the system for commercial purposes. This will be done by providing actual commercial data to define typical running costs, and by generating commercial interest by processing samples supplied by potential customers to demonstrate the iTDE technology’s capabilities commercially. The two planned systems include (i) a smaller flexible system utilizing the iTDE Technology that will enable the processing of solutions containing lithium to demonstrate the commercial viability of the system; and (ii) a larger system that will handle the processing of industrial quantities of brines, better demonstrating the scalability and performance of the system when used commercially to extract lithium.

 

The smaller system was designed to facilitate work on refinement of the basic iTDE system by enabling changes to sensor types and positions as well as adaptations to its other relevant systems. It is expected this will contribute to improvements in efficiency and assist in the modelling of the process for commercial implementation, enabling changes that will reduce the cost and improve the economics of the process. The inherent flexibility of the design also allows the Company to conduct its research into the extraction of other elements thereby exploring the commercial viability of the extraction of other elements.

 

The first system is undergoing trials. The first trials conducted have been positive and have led to a number of alterations to the basic system with certain supplements to improve the processing speed and to reduce costs. The trials and tests should continue through to the first quarter 2025 and it is estimated that testing of customer brines should begin in the first quarter 2025.

 

F-7

 

The Company will run the first extraction tests on brine solutions mixed with controlled defined quantities of single elements followed by controlled mixtures that will approximate the naturally occurring brines of potential customers. The Company has already received small brine samples from Clontarf Energy plc (“Clontarf”), a UK AIM listed company with whom the Company concluded an agreement for iTDE Technology in Bolivia through a jointly established commercial venture. The composition of these brines will be the basis for modeling these controlled samples. This initial calibration of the system will be done by making synthetic brines based upon analytical data received from the Bolivian State Lithium Company and should provide a basis for better testing with actual brines. We expect large container sized samples of actual brines to arrive in India in or about January of 2025 for testing in our pilot plant system.

 

The Company continues to work with it Indian partners to test the effectiveness of proprietary nano-filtration system to use in front of our pilot plant system to remove significant amounts of divalent ions, such as magnesium and calcium, without the use of any chemicals. This may make our complete system more economical in challenging remote areas such as our project with Clontarf in Bolivia.

 

The Company has committed to establishing a small office in India as a permanent base in which to continue its system development and better to manage work with its Indian partners.

 

Due to a lack of funding, the Company has scaled back its intellectual property protection strategy in the near term.

 

NOTE 2 – GOING CONCERN

 

The Company has incurred losses since inception (August 13, 2014) resulting in an accumulated deficit of $ 7,273,354 as of September 30, 2024. Until such time as the pilot plant is completed and the Company can commence the normal commercialization of its technology, further losses are anticipated. Management anticipates more losses before the commercialization of the system can be expected to break-even or to turn a profit. For the nine months ended September 30, 2024, the Company showed a net loss of $1,219,391 as compared with the loss of $1,778,554 for the nine months ended September 30, 2023. The net cash used in operating activities of the Company during the nine months ended September 30, 2024, and 2023 was $1,033,072 and $366,458, respectively. Notwithstanding the receipt of the first income from the commencement of the commercialization of the Company’s main asset, its iTDE Technology, there remains a substantial doubt regarding the Company’s ability to continue as a going concern. Management believes that the Company’s capital requirements will depend on many factors including the continuing and expanding success of the Company’s development efforts. Notwithstanding the promising results of the Company’s participation in its venture with Clontarf and the Government of Bolivia, the Company will require additional capital to reach its goals.

 

From the anticipated receipts of any financing, the Company must discharge outstanding payables of $212,046 and a further $566,250 in accrued expenses. These figures do not include a total of $2,163,254 payable for salary, remuneration and expenses that has been deferred by agreement until the Company is profitable.

 

Provided that the agreements with employees and consultants on the deferral of their outstanding remuneration take effect and the shareholders convert their loans into equity, the Company will need to raise an estimated $3 million to manage its business needs and expansion. There is no assurance that the financing of this nature will be available. The inability to raise the financing necessary and the general business uncertainties and particular conditions and situations described above raise doubts about our ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand, loans from directors and, or the private placement of common stock. There can be no assurances that management’s plans will be successful.

 

F-8

 

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Interim Financial Statements

 

The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim financial statements should be viewed in conjunction with the audited financial statements of the Company for the year ended December 31, 2023.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could and likely will differ from those estimates.

 

Intangible asset

 

Management has classified the iTDE Technology as an indefinite intangible asset based on it being a fundamental stem technology that has applications in numerous fields and that is anticipated to give rise to other applications and process techniques. This means that several additional patents are expected to be generated over the course of a number of years as the basic technology is adapted to different fields. As a result, the Company has recorded no amortization against the asset which remains at its October 1, 2021, value of $3,150,114 (see Note 5 to these unaudited condensed financial statements and disclosure in the preamble to the present 2024 10-Q). The Company conducts regular assessments of the iTDE Technology to identify if its value is impaired in any way, (i) on an annual basis and (ii) if, in the opinion of Management, there exists any external or internal reason why the asset might be impaired. In the opinion of management, as at the date of this report, there exists no external or internal reason why the asset might be impaired.

 

Revenue Recognition

 

The Company utilizes a five-step process when assessing the recognition of revenue from contractual obligations.

 

	(i)	Identification of the type and binding nature of the contract as well as an identification and assessment of the goods and services undertaken with specific reference to the intangible nature of the intellectual property rights sold;
	(ii)	Identification of specific performance obligations within the overall contract that are distinct.
	(iii)	Determination of the specific price or value of the specific performance obligation.
	(iv)	Allocation of the transaction price or value of a specific performance obligation; and
	(v)	Determination of the moment the obligation undertaken is delivered or performance is satisfied.

 

NOTE 4 – PREPAID EXPENSE AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets amounted to $591,070 as of September 30, 2024, it was increased from the $72,925 reported as of December 31, 2023. This represents an increase of $518,145 during the period. Prepaid expenses comprise a $1,600 deposit on the rental of laboratory facilities and a $600 deposit under a consultancy agreement, both unchanged. The remainder comprises advance payments for the purpose of filing for intellectual property protection. Payments are made in trust to our IP attorneys through whom amounts are disbursed when required. The trust account is replenished when needed. Finally, the Company loaned a total amount of $496,025 to a US engineering and materials research corporation under a program controlled by the CEO of the Company that is expected to be repaid by May 30, 2025, together with interest of 10% per annum.

 

F-9

 

NOTE 5 – PRINCIPAL ASSET (iTDE TECHNOLOGY)

 

The Company’s principal asset is the certain indefinite intangible intellectual property, comprising specifically certain patents and patent applications along with the existing and developing knowhow, relating to a novel extraction process proven capable of removing ions from solution using hollow fiber membranes (the “Extraction Technology”). The Extraction Technology represents, in the opinion of management, an entirely novel approach to the process of extraction of ions that is anticipated to be cheaper, more efficient, and less damaging to the environment. Following an assessment of the Extraction Technology conducted at the end of Q3, 2021, it was determined that the Extraction Technology had an indefinite useful life. The said indefinite, intangible asset will not be amortized; however, the value of the Asset will be examined for impairment periodically in accordance with ASC 350. The Company has conducted a review of impairment as on September 30, 2024, and considers that the technology remains unimpaired, therefore at the end of the third quarter 2024, the Extraction Technology is valued on the balance sheet at $3,150,114.

 

NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

As of September 30, 2024, and December 31, 2023, accounts payable and accrued liabilities consisted of as follows:

 SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

		September 30,				December 31
		2024				2023
Accounts payable and accrued expenses		$	905,136			$	698,009
Accrued payroll			1,931,969				1,668,748
Accrued interest			183,598				76,450
Total		$	3,020,703			$	2,443,207

 

As on September 30, 2024, the Company owed a total of $845,000 in loans payable to shareholders. These loans (including their various interest payments) will fall due as follows:

 SCHEDULE OF VARIOUS INTEREST PAYMENTS

Fourth Quarter 2024		$	250,000
2025		$	595,000

 

On February 29, 2024, the Company concluded a total of seven agreements with its senior employees, consultants, and third-party professionals and with one former employee that resigned in January 2024. These agreements set out the terms under which such people would receive their past indebtedness, except for the employee that resigned, their future remuneration. Each of these agreements provides for all the indebtedness due to the respective persons to become due and payable as soon as the Company shall have either (i) achieved an annual EBITDA of $5 million per annum as indicated by reference to the Annual Report of the Company on Form 10-K or if no such report is filed, in accordance with the audited financial reports presented to the shareholders, or, (ii) achieved a quarterly income figure of $12 million, or, (iii) the Board of Directors of the Company shall declare the Indebtedness due. Until such time as payment is made, all Indebtedness shall incur interest at 8%. The Agreements additionally provide for the respective salaries fixed in the employment agreements to be reduced to at least one quarter of the amount of remuneration set forth in the employment or consulting agreement from March 1, 2024. Remuneration will increase to one half of the agreed salary either (a) on the date on which the Company shall raise more than $3 million in equity or debt finance, or (b) the date on which the Company shall receive booked revenue.

 

The agreements further provide for each signatory with the Company to convert all or a portion of the Indebtedness and Penalty Interest to shares of common stock of the Company at any time at the lower of (i) the price which is five percent (5%) lower than the average trading price of the five business trading days immediately preceding the date of the election, or (ii), if the Company is in the process of raising finance and has made an offering to the public by reporting the offering to the Securities Exchange Commission (“SEC”), at the price that is five percent (5%) lower than the price recorded in such reported offering provided such offering shall have been active at any time during the previous quarter.

 

The indebtedness of the Company to the signatories shall be accelerated and become immediately due and payable in the event that the Company shall fail: (i) (a) to achieve an annual EBITDA of $5 million per annum, or, (b) to achieve a quarterly income figure of $12 million, or, (c) to declare the Indebtedness on or before February 28, 2027; or (ii) to pay the monthly remuneration agreed in the agreement within 11 days of the month end in which the remuneration was incurred.

 

F-10

 

Notwithstanding the above, the Indebtedness shall become due on the fifth anniversary of the Execution Date.

 

These agreements shall only enter into force on the first date following February 29, 2024 on which the total debt of the Company outstanding to any listed shareholders of NCX who are not employees of NCX has been either converted to shares of common stock of NCX, or paid in full, or forgiven; if this suspensive condition is not realized on or before May 30, 2025, the agreements all become void, the original deadline having been extended by agreement.

 

As at September 30, 2024 none of these agreements entered into force.

 

NOTE 7 – CONVERTIBLE NOTES, PROMISSARY NOTES AND LOANS

 

During the nine months ended September 30, 2024, the Company issued seventeen Series F convertible notes with aggregate amount of $1,220,004 and will mature in 24 months.

 

As of September 30, 2024, the Company had seventeen outstanding loans with an aggregate value of $1,220,004. Each of these loans is repayable in one year and pays 10% interest annually on arrears. The Company did not contract any loans during the three months ending September 30, 2024.

 

During the nine months ended September 30, 2024, the Company recognized interest expense on its loans and convertible notes of $128,351.

 

NOTE 8 – RELATED PARTY TRANSACTIONS

 

The Company continues to rely on advances from related parties in support of its operations and cash requirements are expected to continue until such time as the Company can support itself or attain adequate financing through sales of equity or debt financing. Most of this support took the form of the nonpayment of all or a portion of salary payments to senior Directors, Officers, consultants, and employees, effectively constituting a deferred debt payment to such people.

 

As of September 30, 2024, Directors, Officers and employees, including full time consultants, were owed a total of $2,163,254 for salaries, remuneration and expenses. Of this $1,988,677 is owed to five senior officers and employees (“Senior Managers”).

 

On May 29, 2024, the Company issued a total of 10,000 newly authorized preferred stock in a newly created class identified as Class “A” Preferred Stock to John Michael Johnson, a director of the Company holding the senior management positions of President and CFO.

 

On September 23, 2024, the Company issued a total of 10,000 newly authorized preferred stock in a newly created class identified as Class “F” Preferred Stock to John Michael Johnson, a director of the Company holding the senior management positions of President and CFO.

 

NOTE 9 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.001 and 5,000,000 shares of preferred stock with a par value of $0.001.

 

On September 30, 2024, there were 28,546,834 shares of common stock outstanding.

 

During the nine months ended September 30, 2024, the Company issued no shares of common stock.

 

F-11

 

On May 29, 2024, the Company Board of Directors issued a total of 20,000 newly authorized preferred stock in a class identified as Class “A” Preferred Stock. Ten thousand (10,000) Class “A” Preferred Stock was issued in the name of John Michael Johnson, a director of the Company holding the senior management positions of President and CFO, and an additional ten thousand (10,000) Class “A” Preferred Stock was issued to the Board of Directors of the Company to utilize as the Board sees fit in the best interest of the Company.

 

Each share of Class A Preferred Stock ranks senior to all Common Stock and any other class of securities that is specifically designated as junior to Class A Preferred Stock. Each Share of Class A Preferred Stock shall be convertible at any time by the holder thereof into 250 shares of Common Stock, however, any Series A Preferred Stock remaining unconverted at 5:00 P.M., Las Vegas, Nevada time on January 1, 2026, shall be automatically converted into Two Hundred Fifty (250) shares of the Company’s Common Stock (par value $0.001). Each Share of Class A Preferred Stock shall be entitled to Five Hundred (500) votes on any matter on which any of the shareholders are required or permitted to vote. No dividends shall be paid on any Series “A” Preferred Stock.

 

On September 23, 2024, the Company Board of Directors issued a total of 20,000 newly authorized preferred stock in a class identified as Class “F” Preferred Stock. Ten thousand (10,000) Class “F” Preferred Stock was issued in the name of John Michael Johnson, a director of the Company holding the senior management positions of President and CFO, and an additional ten thousand (10,000) Class “F” Preferred Stock was issued to the Board of Directors of the Company to utilize as the Board sees fit in the best interest of the Company.

 

Each share of Class F Preferred Stock ranks senior to all Common Stock and any other class of securities. Each Share of Class F Preferred Stock shall not be convertible at any time. Each Share of Class F Preferred Stock shall be entitled to One Thousand (1,000) votes on any matter on which any of the shareholders are required or permitted to vote. No dividends shall be paid on any Series “F” Preferred Stock.

 

During the nine months ended September 30, 2024, the Company issued no options under the Company’s 2021 Stock Incentive Plan (the “Plan”).

 

During the nine months ended September 30, 2024, the Company issued no convertible debt exchangeable into shares of common stock.

 

NOTE 10 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q, and has determined that there have been no such events that have occurred that would require reporting or adjustments to our disclosures.

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Caution Regarding Forward-Looking Information

 

This Quarterly Report on Form 10-Q, including, without limitation, statements containing the words “believes”, “anticipates”, “expects” and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings.

 

Given these uncertainties, readers of this Form 10-Q and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

 

Overview

 

The Company was organized on August 13, 2014, as a Nevada corporation under Chapter 78 of the Nevada Revised Statutes. The Company’s registered address is 3773 Howard Hughes Pkwy STE 500S, Las Vegas, NV, 89169, USA, and its principal office is located at 1980 Festival Plaza Drive, Summerlin South, 300, Las Vegas, NV 89135.

 

The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act which became law in April 2012. The definition of an “emerging growth company” is a company with an initial public offering of common equity securities which occurred after December 8, 2011, and has less than $1 billion of total annual gross revenues during last completed fiscal year.

 

Overview of the Business

 

Since April 27, 2021, the Company has changed its business entirely with the acquisition of intellectual property assets related to a novel membrane-based ion extraction process (“iTDE Technology”), which is able to extract ions exiting in low concentrations from liquid solutions. The iTDE Technology is now being used in laboratory pilot testing to enable the Company to produce its first commercial prototypes using the novel the Extraction method. The iTDE Technology allows for the removal of ions from solution: without concentration by evaporation (significantly preserving the water resources); without pressure or additional heating (reducing energy costs); and targets the specific ions to be extracted (reducing the need for further operations and increasing the potential for the sale of other ions present in the solution). Because of the reduced interference with the environment, the lower energy costs, and the lack of a need for large evaporation ponds, management considers the iTDE Technology to be more environmentally friendly and sustainable when compared to alternatives.

 

The iTDE Technology has been shown effective when extracting lithium from brine solutions or mine leach solutions, and to have significant potential in the following applications: extracting fatty acids from vegetable oils as a superior refining process; extracting glycerides from biodiesel as a superior purification process; extracting radioactive ions from nuclear waste waters; extracting specific metal ions from mine leach solutions and waste effluents; and to remove salts from seawater for desalination, among other things.

 

Currently, the primary focus of the business is on completion of the first of two pilot plants embodying the iTDE Technology system that will enable the demonstration of the extraction system for the extraction of lithium, calcium, magnesium, boron, and certain other elements. The first system will provide greater flexibility to optimize and extend the reach of the process, allowing for replacement of sensor systems and variation of process parameters. It is anticipated that this pilot plant will not only demonstrate the system and its ability to target lithium using naturally occurring brines and liquors (solutions of crushed ores), but also provide a platform to optimize the extraction process and extend the extraction to other elements. The first pilot plant will enable the Company to establish the percentage level of extraction including the purity of the extracted elements and the chemical form of the extracted elements. This will give a clear indication of the economics of the process.

 

A second pilot plant system is planned that will draw on the experience gained from operation of the first pilot plant to improve the current design enabling higher throughputs and a better processing ability for marketing purposes.

 

 

The Company believes it has the ability of the system to scale up due to its modular configuration: adding more units increases the extraction potential. It is anticipated following successful completion and trial and calibration of the iTDE System pilot plant, the Company will launch the commercial testing and deployment of its system that will enable the commercial deployment of the system.

 

Results of Operations

 

The following table summarizes the results of our operations during the six months ended September 30, 2024, and 2023, respectively:

 

		Nine Months Ended
		September 30,
		2024				2023				Change
Revenues		$	-			$	-			$	-
Operating expenses			1,163,868				1,421,663				(257,795	)
Other (Income) expense			55,523				356,891				(301,368	)
Net profit (loss)			(1,219,391	)			(1,778,554	)			(559,163	)
Profit (Loss) per share of common stock			(0.04	)			(0.06	)			(0.02	)

 

Annual expenses as of the third quarter of 2024 were $ 1,219,391 as compared to $1,778,554 to the third quarter of 2023 a reduction of $559,163.

 

The primary reasons for the variation were, first, the exchange of shares conducted under the agreement signed with Clontarf Energy Limited (“Clontarf”) that governs the introduction of the Company’s technology into the Bolivian market and second a general reduction in all expenses compared to the previous period.

 

Under the Clontarf agreement, the Company was obliged to transfer to Clontarf shares of its common stock to the value of $500,000 and this resulted in an expense of $500,000. As part of the mutual obligations under the said agreement, the Company received from Clontarf shares with a value of $ $203,050 recorded in Other Income.

 

During the nine months ending September 30, 2024, the Company invested a total of $496,025 in to a company involved in certain R&D and investments designed to benefit and assist the Company. During the same period, the Company increased its investment into this Company by $48,100 and booked interest income of $72,826 from loans made this third party company.

 

The expense of contractors increased by $136,570 as a result of the need to hire back the services of an employee that left the Company in January 2024. This was considered necessary because of the need to reaudit the Company’s financial statements and other ongoing required work.

 

As of the third quarter of 2024, the Company booked interest expense of $41,359 on the indebtedness of long-standing unpaid salaries to senior employees leading to an increase in employee benefits.

 

There was a decrease in all other expenses during the nine-month period to September 30, 2024 by $421,163 compared to the previous period.

 

To fund the Company’s operations, the Company contracted new loans and extended loans falling due which resulted in an increase of $68,408 in loan interest recorded over the same period in 2023. All interest under these shareholder loans is due at the end of the loan period on the settlement date.

 

Liquidity and Capital Resources

 

As of September 30, 2024, we had total current assets of $694,685 and an accumulated deficit of $7,273,354.

 

Our operating activities used $1,033,072 in cash for the nine months ended September 30, 2024, while our operations used $366,458 cash in the nine months ended September 30, 2023. Operating activities included loans to a third party company amounting to $496,025 expected to be returned with interest during second quarter 2025. During this period, the Company has focused attention on the work necessary to complete the pilot plants. Strategically it was considered necessary to complete the pilot plants to enable the Company to move to the next stage of its marketing plan: to demonstrate the system and its extraction economics to potential users. The Company currently has several companies interested in evaluating the system using their brines and these tests will consume a considerable amount of time once the pilot plants are ready to process. Management considers it preferable to focus on this work, and this has led to an overall reduction in expenses prior to reengaging in other activities.

 

 

Our cash requirements continue to be primarily for the manufacture of the iTDE System pilot plant with the purchase of equipment, materials and operating expenses for the development of pilot plant systems, payroll, intellectual and other expenses. During fiscal 2024 the Company plans to open new corporate offices and commence the organization of its initial production facility based on the results of the Pilot Plant trials.

 

Historically we have depended on investment from our principal shareholders and their affiliated companies to provide us with working capital as required as well as the forbearance of our employees and consultants to forgo all or part of their contracted salaries. There is no guarantee that such funding or other sources of funding will be available when required and there can be no assurance that our stockholders and employees, or any of them, will continue making loans or advances to us in the future.

 

Off Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity or capital expenditures or capital resources that is material to an investor in our securities.

 

Seasonality

 

Our operating results are not affected by seasonality.

 

Inflation

 

The Company has in the past used funding from debt convertible equity as its primary source of funding. In the event of a high inflationary environment, this method of funding may become more expensive and may be less readily available. Our core business and operating results are not affected in any material way by inflation.

 

Critical Accounting Policies

 

Our financial statements and accompanying notes have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates, judgments, and assumptions that affect reported amounts of assets, liabilities, revenues, and expenses. We continually evaluate the accounting policies and estimates used to prepare financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and assumptions and are critical to our results of operations and financial position. Our critical accounting estimates are discussed in Note 2 to our unaudited financial statements contained herein.

 

Item 3 - Quantitative and Qualitative Disclosures About Market Risk

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

 

Item 4 - Controls and Procedures

 

Disclosure of Controls and Procedures

 

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Such information is accumulated and communicated to the Company’s management, including the Company’s chief executive officer (who is the Company’s principal executive officer) and the Company’s President (who is the Company’s chief operating officer) as well as its Financial Officer (the Company’s principal financial officer) to allow for timely decisions regarding required disclosure. At present one person combines the roles of President and Chief Financial Officer. In designing and evaluating the Company’s disclosure controls and procedures, the Company’s management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. The Company’s management is required to apply its judgment in evaluating the cost-benefit relationship with possible controls and procedures. The ineffectiveness of the Company’s disclosure controls and procedures was due to material weaknesses identified in the Company’s internal control over financial reporting, described below.

 

Management’s Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over the Company’s financial reporting. To evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act of 2002. Our management, with the participation of the Company’s principal executive officer and principal financial officer has conducted an assessment, including testing, using the criteria in Internal Control - Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) (2013). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. This assessment included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls and a conclusion on this evaluation.

 

Based on this evaluation, the Company’s management concluded its internal control over financial reporting, while significantly improved, was still not effective as of September 30, 2024.

 

Changes in Internal Control Over Financial Reporting

 

Principal financial controls are managed by the Company’s controller who maintains the accounts under the supervision of the Chief Financial Officer. At present the Company still relies on advances by officers and employees using their own means of payment to fund the Company, these are then repaid (or accumulated as debt) against an accounting of such expenses. The Company plans to issue its own means of payment in the future that would improve efficiency and transparency. The Company changed its bankers during the course of the third quarter 2023. While we believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any Company have been detected, the Company continues to improve its control environment with a view to establishing an effective control environment and to satisfying the Company auditors of the same.

 

 

PART II

OTHER INFORMATION

 

Item 1 - Legal Proceedings

 

On April 26, 2024, Judge Elizabeth Leonard of the Midland County District Court in Midland, Texas entered a Third Turnover Order (the “Turnover Order”) requiring the Company to turn over 15,866,096 of its common shares, registered to a corporation with the same name as the Company (NEXT-ChemX Corporation) but registered in a different jurisdiction. Although the several Turnover Orders provided for the transfer of shares to Sparkie Properties L.L.C. (“Sparkie”) that is managed by Glenn A. Little, who was also appointed receiver of the privately held Texas corporation that owned the shares in the Nevada public company. The Third Turnover Order provided that the shares be turned over to “NEXT-ChemX Corporation”, a Texas corporation, Glenn A. Little, as Director and Receiver”.

 

This decree was issued, even though neither the privately held shareholder in the Company with the same name of NEXT-ChemX Corporation but chartered in Texas, nor the Company itself was ever involved in the underlying lawsuit giving rise to said decree. The order arose from litigation in Sparkie Properties L.L.C. v. NextMetals Limited and Benton Wilcoxon, CV 58242, In the District Court of Midland County, Texas, 238^thJudicial District. The shares of the Company owned by NEXT-ChemX Corporation, the privately held Texas corporation, were alleged, erroneously, to belong to NextMetals Limited, a defendant in the litigation, rather than the actual equity owner of the shares, to wit, the aforementioned closely held private company.

 

In fact, NextMetals Limited, a Gibraltar corporation defendant in the litigation owns shares in the closely held private company, NEXT-ChemX Corporation. Irrespective of that fact, Judge Leonard’s erroneous order mandated the seizure and transfer of the private Texas Company’s assets, which were shares in the Nevada public company, and not the stock in the private Texas company, which shares the same name as the Nevada public corporation.

 

The similarity of names between the Company and the private Texas corporation came about in 2021. At that time, the Company changed its business model and adopted the name of its principal shareholder that contributed the technology currently exploited by the Company. In exchange for an assignment of these novel and potentially disruptive technologies, the private Texas entity was awarded a controlling number of shares. These material facts were ignored by the Court. Moreover, when the private Texas Company whose assets were under threat of seizure and unquestioned transfer to the receiver, the Texas company petitioned the Court to be heard. The trial court judge, contrary to standard practice and tradition in Texas courts, refused to schedule a hearing to consider the merits of the Texas company’s written briefs and motion for oral argument and proceeded to enter a judgment, effectively depriving the private Texas company of its major asset.

 

The aforementioned Turnover Order is not a final order. It is the intention of management to appeal this erroneous ruling to the Texas Court of Appeals for the Eleventh District, located in Eastland, Texas. A notice of appeal has already been filed and the issue will be contested in briefs submitted by the Company’s counsel in the early Fall of 2024. The filing of the appeal suspends enforcement of Judge Leonard’s order until further action by the appellate court.

 

In addition, the Company has engaged an experienced securities attorney to file a formal complaint with the U.S. Securities and Exchange Commission (the “SEC”) in Washington, D.C. with respect to Sparkie Properties L.L.C.’s unlawful attempt to transfer the 15,866,096 common shares issued by the Company belonging to the Texas chartered NEXT-ChemX Corporation. The Company’s lawyer will seek the opening of an investigation from the SEC’s Enforcement Division into the transaction that led to the Turnover Order and a federal injunction from the U.S. District Court for the District of Nevada freezing the shares covered by the Turnover Order until the Court determines the validity of the Third Turnover Order.

 

Simultaneously, the Company’s Nevada counsel intends to file a complaint in the U.S. District Court for Nevada (Las Vegas Division) seeking damages and an immediate recission of the Turnover Order, alleging tortious interference with the right to contract, an unlawful taking of property without compensation, and material violations of various federal and state securities laws.

 

When the Company received notice from its transfer agent, Empire Stock Transfer Inc. (“Empire”) of Henderson, Nevada that, irrespective of the ongoing appeal of the Turnover Order and the fact that the shares covered by the Turnover Order were not the property of Sparkie Properties, L.L.C., Empire nevertheless advised the Company that it intended to issue and transfer to the receiver the shares covered by the Turnover Order. The Company immediately terminated Empire as its transfer agent. This was done via an email and letter delivered on May 23, 2024, in which Empire acknowledged its receipt of the termination notice.

 

Although Empire no longer represented NEXT-ChemX Corporation, the Nevada public company, Empire promptly cancelled the shares owned by NEXT-ChemX Corporation, the closely held private corporation and issued 15,866,096 common shares in the public company divided into two share certificates to NEXT-ChemX Corporation, a Texas corporation, Glenn A. Little, as Director and Receiver.

 

The Company and its attorneys believe the Turnover Order is illegal for reasons stated in a brief timely filed by attorneys for Benton Wilcoxon and NextMetals Ltd with the Texas Court of Appeals.

 

Item 1A – Risk Factors

 

Not applicable.

 

Item 2 - Sales of Unregistered Equity Securities and Use of Proceeds

 

None.

 

Item 3 - Defaults upon Senior Securities

 

None

 

Item 4 - Mine Safety Disclosures

 

Not applicable.

 

Item 5 - Other Information

 

None

 

 

ITEM 6. EXHIBITS.

 

The following exhibits are filed as part of this report or incorporated by reference:

 

Exhibit No.		Description
31.1*		Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101*		Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q.
104*		Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.

 

* Filed herewith

** Furnished herewith

 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 19, 2024	NEXT-ChemX Corporation
	By:	/s/ Benton Wilcoxon
		Benton Wilcoxon
		Chief Executive Officer
		(Principal Executive Officer)

 

 

 

Exhibit 31.1

 

CERTIFICATION

 

I, Benton Wilcoxon, certify that:

 

1.	I have reviewed this Form 10-Q of NEXT-ChemX Corporation;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 19, 2024	By:	/s/ Benton Wilcoxon
		Benton Wilcoxon
		Principal Executive Officer

 

 

 

Exhibit 31.2

 

CERTIFICATION

 

I, J. Michael Johnson, certify that:

 

1.	I have reviewed this Form 10-Q of NEXT-ChemX Corporation;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 19, 2024	By:	/s/ J. Michael Johnson
		J. Michael Johnson
		Principal Financial Officer

 

 

 

Exhibit 32.1

 

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report of NEXT-ChemX Corporation (the “Company”), on Form 10-Q for the period ended September 30, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, Benton Wilcoxon, Principal Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

	(1)	Such Quarterly Report on Form 10-Q for the period ended September 30, 2024, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
	(2)	The information contained in such Quarterly Report on Form 10-Q for the period ended September 30, 2024, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 19, 2024	By:	/s/ Benton Wilcoxon
		Benton Wilcoxon
		Chief Executive Officer
		(Principal Executive Officer)

 

In connection with this Quarterly Report of NEXT-ChemX Corporation (the “Company”), on Form 10-Q for the period ended September 30, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, J. Michael Johnson, Principal Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

	(1)	Such Quarterly Report on Form 10-Q for the period ended September 30, 2024, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
	(2)	The information contained in such Quarterly Report on Form 10-Q for the period ended September 30, 2024, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 19, 2024	By:	/s/ J. Michael Johnson
		J. Michael Johnson
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

 

 

 

v3.24.3

Cover - $ / shares	9 Months Ended
	Sep. 30, 2024	Nov. 18, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	000-56379
Entity Registrant Name	NEXT-ChemX Corporation
Entity Central Index Key	0001657045
Entity Tax Identification Number	32-0446353
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	1980 Festival Plaza Drive
Entity Address, Address Line Two	Summerlin South
Entity Address, Address Line Three	Suite 300
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89135
City Area Code	(725)
Local Phone Number	867-0789
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		28,546,834
Entity Common Stock, Shares Outstanding	$ 0.001

v3.24.3

Condensed Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 35,386	$ 2,458
Financial Assets	68,229	64,944
Prepaid expense and other current assets	591,070	72,925
Total Current Assets	694,685	140,327
Property and equipment, net	8,619	12,621
Intangible asset, net	3,150,114	3,150,114
Total Non-current Assets	3,158,733	3,162,735
Total Assets	3,853,418	3,303,062
Current Liabilities:
Accounts payable and accrued liabilities	3,020,703	2,443,207
Loan payable	845,000	945,000
Total Current Liabilities	4,482,128	3,932,425
Non-Current Liabilities:
Notes payable	1,220,004
Total Non-Current Liabilities	1,220,004
Total Liabilities	5,702,132	3,932,425
Stockholders’ Equity (Deficit):
Common stock, $0.001 par value, 100,000,000 shares authorized; 28,546,834 issued and outstanding	28,547	28,547
Additional paid-in capital	5,396,053	5,396,053
Accumulated deficit	(7,273,354)	(6,053,963)
Total Stockholders’ Equity (Deficit)	(1,848,714)	(629,363)
Total Liabilities and Stockholders’ Equity (Deficit)	3,853,418	3,303,062
Series A Preferred Stock [Member]
Stockholders’ Equity (Deficit):
Preferred stock, value	20
Series F Preferred Stock [Member]
Stockholders’ Equity (Deficit):
Preferred stock, value	20
Nonrelated Party [Member]
Current Liabilities:
Other Current Liabilities	511,980	511,980
Related Party [Member]
Current Liabilities:
Other Current Liabilities	$ 104,445	$ 32,238

v3.24.3

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	28,546,834	28,546,834
Common stock, shares outstanding	28,546,834	28,546,834
Series A Preferred Stock [Member]
Preferred stock, shares issued	20,000
Preferred stock, shares outstanding	20,000
Series F Preferred Stock [Member]
Preferred stock, shares issued	20,000
Preferred stock, shares outstanding	20,000

v3.24.3

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenues
Operating expenses
General and administrative	319,441	403,435	1,163,868	1,421,663
Total operating expenses	319,441	403,435	1,163,868	1,421,663
Income (loss) from operations	(319,441)	(403,435)	(1,163,868)	(1,421,663)
Other income (expense)
Other income (expense)	14,401	(500,000)	72,828	(296,947)
Interest expense	(49,455)	(19,422)	(128,351)	(59,944)
Net other Income (expense)	(35,054)	(519,422)	(55,523)	(356,891)
Net income (loss)	$ (354,495)	$ (922,857)	$ (1,219,391)	$ (1,778,554)
Net income (loss) per common share, Basic	$ (0.01)	$ (0.03)	$ (0.04)	$ (0.06)
Net income (loss) per common share, Diluted	$ (0.01)	$ (0.03)	$ (0.04)	$ (0.06)
Weighted average number of common shares outstanding, Basic	28,546,834	28,495,747	28,546,834	28,439,508
Weighted average number of common shares outstanding, Diluted	28,546,834	28,495,747	28,546,834	28,439,508

v3.24.3

Condensed Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022		$ 28,347	$ 4,396,253	$ (3,692,732)	$ 731,868
Balance, shares at Dec. 31, 2022		28,346,834
Net loss				(457,973)	(457,973)
Stock Issuances to 3rd Party		$ 100	499,900		500,000
Stock Issuances to 3rd Party, shares		100,000
Balance at Mar. 31, 2023		$ 28,447	4,896,153	(4,150,705)	773,895
Balance, shares at Mar. 31, 2023		28,446,834
Balance at Dec. 31, 2022		$ 28,347	4,396,253	(3,692,732)	731,868
Balance, shares at Dec. 31, 2022		28,346,834
Net loss					(1,778,554)
Balance at Sep. 30, 2023		$ 28,547	5,396,053	(5,471,286)	(46,686)
Balance, shares at Sep. 30, 2023		28,546,834
Balance at Mar. 31, 2023		$ 28,447	4,896,153	(4,150,705)	773,895
Balance, shares at Mar. 31, 2023		28,446,834
Net loss				(397,724)	(397,724)
Balance at Jun. 30, 2023		$ 28,447	4,896,153	(4,548,428)	376,171
Balance, shares at Jun. 30, 2023		28,446,834
Net loss				(922,857)	(922,857)
Stock Issuances to 3rd Party		$ 100	499,900		500,000
Stock Issuances to 3rd Party, shares		100,000
Balance at Sep. 30, 2023		$ 28,547	5,396,053	(5,471,286)	(46,686)
Balance, shares at Sep. 30, 2023		28,546,834
Balance at Dec. 31, 2023		$ 28,547	5,396,053	(6,053,963)	(629,363)
Balance, shares at Dec. 31, 2023		28,546,834
Net loss				(518,963)	(518,963)
Balance at Mar. 31, 2024		$ 28,547	5,396,053	(6,572,926)	(1,148,326)
Balance, shares at Mar. 31, 2024		28,546,834
Balance at Dec. 31, 2023		$ 28,547	5,396,053	(6,053,963)	(629,363)
Balance, shares at Dec. 31, 2023		28,546,834
Net loss					(1,219,391)
Issuance of Preferred Stocks, shares		0
Balance at Sep. 30, 2024	$ 40	$ 28,547	5,396,053	(7,273,354)	(1,848,714)
Balance, shares at Sep. 30, 2024	40,000	28,546,834
Balance at Mar. 31, 2024		$ 28,547	5,396,053	(6,572,926)	(1,148,326)
Balance, shares at Mar. 31, 2024		28,546,834
Net loss				(345,933)	(345,933)
Issuance of Preferred Stocks	$ 20				20
Issuance of Preferred Stocks, shares	20,000
Balance at Jun. 30, 2024	$ 20	$ 28,547	5,396,053	(6,918,859)	(1,494,239)
Balance, shares at Jun. 30, 2024	20,000	28,546,834
Net loss				(354,495)	(354,495)
Issuance of Preferred Stocks	$ 20				20
Issuance of Preferred Stocks, shares	20,000
Balance at Sep. 30, 2024	$ 40	$ 28,547	$ 5,396,053	$ (7,273,354)	$ (1,848,714)
Balance, shares at Sep. 30, 2024	40,000	28,546,834

v3.24.3

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net income(loss)	$ (1,219,391)	$ (1,778,554)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,002	4,002
Other income received in form Shares of Stocks		(203,050)
Other Expense paid in stocks		500,000
Consultant commission paid in third party stock		101,525
Unrealized gain on trading securities	(3,285)
Changes in Operating Assets and Liabilities:
Related Party Advances	72,247
Prepaid expenses and other assets	(518,145)	(50,760)
Accounts payable and accrued liabilities	631,500	1,060,379
Net cash provided by (used in) operating activities	(1,033,072)	(366,458)
INVESTING ACTIVITIES
Purchase of property and equipment
Net cash provided by (used in) investing activities
FINANCING ACTIVITIES
Proceeds from the Stock Issuance of Common Stocks		500,000
Proceeds from convertible notes payable		345,000
Net proceeds from convertible notes payable	1,046,000
Net proceeds from loan payable	20,000
Repayment of notes payable		(446,007)
Net cash provided by (used in) financing activities	1,066,000	398,993
Net increase (decrease) in cash	32,928	32,535
Cash, beginning of year	2,458	28,355
Cash, end of the period	35,386	60,890
Cash paid during the period for:
Income tax
Interest		37,212
NON-CASH INVESTING AND FINANCING ACTIVITIES
Conversion of loan, interest and debt to convertible note	174,004
Issuance of Preferred Stocks against Indebtedness	$ 40

v3.24.3

ORGANIZATION AND BUSINESS OPERATIONS	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
ORGANIZATION AND BUSINESS OPERATIONS	NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS   Organization and Description of Business   NEXT-ChemX Corporation, formerly known as AllyMe Group Inc. (the “Company”, “we” or “us”) was incorporated under the laws of the State of Nevada on August 13, 2014, and has adopted a December 31 fiscal year end. The Company trades on the OTC market (Pink Sheet) under the symbol “CHMX”. On December 23, 2021, the Company filed SEC Form 8 A12G becoming a mandatory filer and has since complied with all reporting requirements of the Securities Exchange Commission as a reporting issuer.   Since April 2021, following a complete change of the Company’s shareholders, management, assets and strategy, the business of the Company became the commercialization of a novel innovative Ion-Targeting Continuous-Flow Direct Extraction Technology (“iTDE Technology”) as further described in Note 5 below. The iTDE Technology is embodied in certain patents and patent applications as well as proprietary knowledge.   The primary focus of the Company is the commercial launch of its iTDE Technology in a scalable system and cost-effective system that may be deployed remotely to customer locations. The Company’s technology, when fully tested and implemented, is expected to enable the commercial extraction of lithium from natural brines and geothermal sources as well as liquors from leached mined ore solutions. In addition, since the first quarter of 2024, management began to focus on developing two or three other targeted systems for the mining of metals as well as water treatment systems and recycling.   Potential future commercial applications for the iTDE Technology include, but are not limited to:     ● Extracting Fatty Acids from Vegetable Oils for More Economical Refining;   ● Extracting of Radioactive Ions from Nuclear Plant Stored Water;   ● Extracting of Metal Ions from Mine Leach Solutions, Effluent, or Tailings; and   ● Desalination of Sea Water, by Extracting Ions for Water Purification   During the first nine months of 2024, the Company has continued to manage the construction of the first of two pilot plant systems that will form the basis of its ongoing commercialization efforts by demonstrating the scalability of the system for commercial purposes. This will be done by providing actual commercial data to define typical running costs, and by generating commercial interest by processing samples supplied by potential customers to demonstrate the iTDE technology’s capabilities commercially. The two planned systems include (i) a smaller flexible system utilizing the iTDE Technology that will enable the processing of solutions containing lithium to demonstrate the commercial viability of the system; and (ii) a larger system that will handle the processing of industrial quantities of brines, better demonstrating the scalability and performance of the system when used commercially to extract lithium.   The smaller system was designed to facilitate work on refinement of the basic iTDE system by enabling changes to sensor types and positions as well as adaptations to its other relevant systems. It is expected this will contribute to improvements in efficiency and assist in the modelling of the process for commercial implementation, enabling changes that will reduce the cost and improve the economics of the process. The inherent flexibility of the design also allows the Company to conduct its research into the extraction of other elements thereby exploring the commercial viability of the extraction of other elements.   The first system is undergoing trials. The first trials conducted have been positive and have led to a number of alterations to the basic system with certain supplements to improve the processing speed and to reduce costs. The trials and tests should continue through to the first quarter 2025 and it is estimated that testing of customer brines should begin in the first quarter 2025.     The Company will run the first extraction tests on brine solutions mixed with controlled defined quantities of single elements followed by controlled mixtures that will approximate the naturally occurring brines of potential customers. The Company has already received small brine samples from Clontarf Energy plc (“Clontarf”), a UK AIM listed company with whom the Company concluded an agreement for iTDE Technology in Bolivia through a jointly established commercial venture. The composition of these brines will be the basis for modeling these controlled samples. This initial calibration of the system will be done by making synthetic brines based upon analytical data received from the Bolivian State Lithium Company and should provide a basis for better testing with actual brines. We expect large container sized samples of actual brines to arrive in India in or about January of 2025 for testing in our pilot plant system.   The Company continues to work with it Indian partners to test the effectiveness of proprietary nano-filtration system to use in front of our pilot plant system to remove significant amounts of divalent ions, such as magnesium and calcium, without the use of any chemicals. This may make our complete system more economical in challenging remote areas such as our project with Clontarf in Bolivia.   The Company has committed to establishing a small office in India as a permanent base in which to continue its system development and better to manage work with its Indian partners.   Due to a lack of funding, the Company has scaled back its intellectual property protection strategy in the near term.

v3.24.3

GOING CONCERN	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN   The Company has incurred losses since inception (August 13, 2014) resulting in an accumulated deficit of $ 7,273,354 as of September 30, 2024. Until such time as the pilot plant is completed and the Company can commence the normal commercialization of its technology, further losses are anticipated. Management anticipates more losses before the commercialization of the system can be expected to break-even or to turn a profit. For the nine months ended September 30, 2024, the Company showed a net loss of $1,219,391 as compared with the loss of $1,778,554 for the nine months ended September 30, 2023. The net cash used in operating activities of the Company during the nine months ended September 30, 2024, and 2023 was $1,033,072 and $366,458, respectively. Notwithstanding the receipt of the first income from the commencement of the commercialization of the Company’s main asset, its iTDE Technology, there remains a substantial doubt regarding the Company’s ability to continue as a going concern. Management believes that the Company’s capital requirements will depend on many factors including the continuing and expanding success of the Company’s development efforts. Notwithstanding the promising results of the Company’s participation in its venture with Clontarf and the Government of Bolivia, the Company will require additional capital to reach its goals.   From the anticipated receipts of any financing, the Company must discharge outstanding payables of $212,046 and a further $566,250 in accrued expenses. These figures do not include a total of $2,163,254 payable for salary, remuneration and expenses that has been deferred by agreement until the Company is profitable.   Provided that the agreements with employees and consultants on the deferral of their outstanding remuneration take effect and the shareholders convert their loans into equity, the Company will need to raise an estimated $3 million to manage its business needs and expansion. There is no assurance that the financing of this nature will be available. The inability to raise the financing necessary and the general business uncertainties and particular conditions and situations described above raise doubts about our ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.   The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand, loans from directors and, or the private placement of common stock. There can be no assurances that management’s plans will be successful.

v3.24.3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Interim Financial Statements   The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim financial statements should be viewed in conjunction with the audited financial statements of the Company for the year ended December 31, 2023.   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could and likely will differ from those estimates.   Intangible asset   Management has classified the iTDE Technology as an indefinite intangible asset based on it being a fundamental stem technology that has applications in numerous fields and that is anticipated to give rise to other applications and process techniques. This means that several additional patents are expected to be generated over the course of a number of years as the basic technology is adapted to different fields. As a result, the Company has recorded no amortization against the asset which remains at its October 1, 2021, value of $3,150,114 (see Note 5 to these unaudited condensed financial statements and disclosure in the preamble to the present 2024 10-Q). The Company conducts regular assessments of the iTDE Technology to identify if its value is impaired in any way, (i) on an annual basis and (ii) if, in the opinion of Management, there exists any external or internal reason why the asset might be impaired. In the opinion of management, as at the date of this report, there exists no external or internal reason why the asset might be impaired.   Revenue Recognition   The Company utilizes a five-step process when assessing the recognition of revenue from contractual obligations.     (i) Identification of the type and binding nature of the contract as well as an identification and assessment of the goods and services undertaken with specific reference to the intangible nature of the intellectual property rights sold;   (ii) Identification of specific performance obligations within the overall contract that are distinct.   (iii) Determination of the specific price or value of the specific performance obligation.   (iv) Allocation of the transaction price or value of a specific performance obligation; and   (v) Determination of the moment the obligation undertaken is delivered or performance is satisfied.

v3.24.3

PREPAID EXPENSE AND OTHER CURRENT ASSETS	9 Months Ended
	Sep. 30, 2024
Prepaid Expense and Other Assets, Current [Abstract]
PREPAID EXPENSE AND OTHER CURRENT ASSETS	NOTE 4 – PREPAID EXPENSE AND OTHER CURRENT ASSETS   Prepaid expenses and other current assets amounted to $591,070 as of September 30, 2024, it was increased from the $72,925 reported as of December 31, 2023. This represents an increase of $518,145 during the period. Prepaid expenses comprise a $1,600 deposit on the rental of laboratory facilities and a $600 deposit under a consultancy agreement, both unchanged. The remainder comprises advance payments for the purpose of filing for intellectual property protection. Payments are made in trust to our IP attorneys through whom amounts are disbursed when required. The trust account is replenished when needed. Finally, the Company loaned a total amount of $496,025 to a US engineering and materials research corporation under a program controlled by the CEO of the Company that is expected to be repaid by May 30, 2025, together with interest of 10% per annum.

v3.24.3

PRINCIPAL ASSET (iTDE TECHNOLOGY)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
PRINCIPAL ASSET (iTDE TECHNOLOGY)	NOTE 5 – PRINCIPAL ASSET (iTDE TECHNOLOGY)   The Company’s principal asset is the certain indefinite intangible intellectual property, comprising specifically certain patents and patent applications along with the existing and developing knowhow, relating to a novel extraction process proven capable of removing ions from solution using hollow fiber membranes (the “Extraction Technology”). The Extraction Technology represents, in the opinion of management, an entirely novel approach to the process of extraction of ions that is anticipated to be cheaper, more efficient, and less damaging to the environment. Following an assessment of the Extraction Technology conducted at the end of Q3, 2021, it was determined that the Extraction Technology had an indefinite useful life. The said indefinite, intangible asset will not be amortized; however, the value of the Asset will be examined for impairment periodically in accordance with ASC 350. The Company has conducted a review of impairment as on September 30, 2024, and considers that the technology remains unimpaired, therefore at the end of the third quarter 2024, the Extraction Technology is valued on the balance sheet at $3,150,114.

v3.24.3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES   As of September 30, 2024, and December 31, 2023, accounts payable and accrued liabilities consisted of as follows:  SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES     September 30,     December 31       2024     2023   Accounts payable and accrued expenses   $ 905,136     $ 698,009   Accrued payroll     1,931,969       1,668,748   Accrued interest     183,598       76,450   Total   $ 3,020,703     $ 2,443,207     As on September 30, 2024, the Company owed a total of $845,000 in loans payable to shareholders. These loans (including their various interest payments) will fall due as follows:  SCHEDULE OF VARIOUS INTEREST PAYMENTS           Fourth Quarter 2024   $ 250,000   2025   $ 595,000     On February 29, 2024, the Company concluded a total of seven agreements with its senior employees, consultants, and third-party professionals and with one former employee that resigned in January 2024. These agreements set out the terms under which such people would receive their past indebtedness, except for the employee that resigned, their future remuneration. Each of these agreements provides for all the indebtedness due to the respective persons to become due and payable as soon as the Company shall have either (i) achieved an annual EBITDA of $5 million per annum as indicated by reference to the Annual Report of the Company on Form 10-K or if no such report is filed, in accordance with the audited financial reports presented to the shareholders, or, (ii) achieved a quarterly income figure of $12 million, or, (iii) the Board of Directors of the Company shall declare the Indebtedness due. Until such time as payment is made, all Indebtedness shall incur interest at 8%. The Agreements additionally provide for the respective salaries fixed in the employment agreements to be reduced to at least one quarter of the amount of remuneration set forth in the employment or consulting agreement from March 1, 2024. Remuneration will increase to one half of the agreed salary either (a) on the date on which the Company shall raise more than $3 million in equity or debt finance, or (b) the date on which the Company shall receive booked revenue.   The agreements further provide for each signatory with the Company to convert all or a portion of the Indebtedness and Penalty Interest to shares of common stock of the Company at any time at the lower of (i) the price which is five percent (5%) lower than the average trading price of the five business trading days immediately preceding the date of the election, or (ii), if the Company is in the process of raising finance and has made an offering to the public by reporting the offering to the Securities Exchange Commission (“SEC”), at the price that is five percent (5%) lower than the price recorded in such reported offering provided such offering shall have been active at any time during the previous quarter.   The indebtedness of the Company to the signatories shall be accelerated and become immediately due and payable in the event that the Company shall fail: (i) (a) to achieve an annual EBITDA of $5 million per annum, or, (b) to achieve a quarterly income figure of $12 million, or, (c) to declare the Indebtedness on or before February 28, 2027; or (ii) to pay the monthly remuneration agreed in the agreement within 11 days of the month end in which the remuneration was incurred.     Notwithstanding the above, the Indebtedness shall become due on the fifth anniversary of the Execution Date.   These agreements shall only enter into force on the first date following February 29, 2024 on which the total debt of the Company outstanding to any listed shareholders of NCX who are not employees of NCX has been either converted to shares of common stock of NCX, or paid in full, or forgiven; if this suspensive condition is not realized on or before May 30, 2025, the agreements all become void, the original deadline having been extended by agreement.   As at September 30, 2024 none of these agreements entered into force.

v3.24.3

CONVERTIBLE NOTES, PROMISSARY NOTES AND LOANS	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
CONVERTIBLE NOTES, PROMISSARY NOTES AND LOANS	NOTE 7 – CONVERTIBLE NOTES, PROMISSARY NOTES AND LOANS   During the nine months ended September 30, 2024, the Company issued seventeen Series F convertible notes with aggregate amount of $1,220,004 and will mature in 24 months.   As of September 30, 2024, the Company had seventeen outstanding loans with an aggregate value of $1,220,004. Each of these loans is repayable in one year and pays 10% interest annually on arrears. The Company did not contract any loans during the three months ending September 30, 2024.   During the nine months ended September 30, 2024, the Company recognized interest expense on its loans and convertible notes of $128,351.

v3.24.3

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 8 – RELATED PARTY TRANSACTIONS   The Company continues to rely on advances from related parties in support of its operations and cash requirements are expected to continue until such time as the Company can support itself or attain adequate financing through sales of equity or debt financing. Most of this support took the form of the nonpayment of all or a portion of salary payments to senior Directors, Officers, consultants, and employees, effectively constituting a deferred debt payment to such people.   As of September 30, 2024, Directors, Officers and employees, including full time consultants, were owed a total of $2,163,254 for salaries, remuneration and expenses. Of this $1,988,677 is owed to five senior officers and employees (“Senior Managers”).   On May 29, 2024, the Company issued a total of 10,000 newly authorized preferred stock in a newly created class identified as Class “A” Preferred Stock to John Michael Johnson, a director of the Company holding the senior management positions of President and CFO.   On September 23, 2024, the Company issued a total of 10,000 newly authorized preferred stock in a newly created class identified as Class “F” Preferred Stock to John Michael Johnson, a director of the Company holding the senior management positions of President and CFO.

v3.24.3

STOCKHOLDERS’ EQUITY (DEFICIT)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIT)	NOTE 9 – STOCKHOLDERS’ EQUITY (DEFICIT)   The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.001 and 5,000,000 shares of preferred stock with a par value of $0.001.   On September 30, 2024, there were 28,546,834 shares of common stock outstanding.   During the nine months ended September 30, 2024, the Company issued no shares of common stock.     On May 29, 2024, the Company Board of Directors issued a total of 20,000 newly authorized preferred stock in a class identified as Class “A” Preferred Stock. Ten thousand (10,000) Class “A” Preferred Stock was issued in the name of John Michael Johnson, a director of the Company holding the senior management positions of President and CFO, and an additional ten thousand (10,000) Class “A” Preferred Stock was issued to the Board of Directors of the Company to utilize as the Board sees fit in the best interest of the Company.   Each share of Class A Preferred Stock ranks senior to all Common Stock and any other class of securities that is specifically designated as junior to Class A Preferred Stock. Each Share of Class A Preferred Stock shall be convertible at any time by the holder thereof into 250 shares of Common Stock, however, any Series A Preferred Stock remaining unconverted at 5:00 P.M., Las Vegas, Nevada time on January 1, 2026, shall be automatically converted into Two Hundred Fifty (250) shares of the Company’s Common Stock (par value $0.001). Each Share of Class A Preferred Stock shall be entitled to Five Hundred (500) votes on any matter on which any of the shareholders are required or permitted to vote. No dividends shall be paid on any Series “A” Preferred Stock.   On September 23, 2024, the Company Board of Directors issued a total of 20,000 newly authorized preferred stock in a class identified as Class “F” Preferred Stock. Ten thousand (10,000) Class “F” Preferred Stock was issued in the name of John Michael Johnson, a director of the Company holding the senior management positions of President and CFO, and an additional ten thousand (10,000) Class “F” Preferred Stock was issued to the Board of Directors of the Company to utilize as the Board sees fit in the best interest of the Company.   Each share of Class F Preferred Stock ranks senior to all Common Stock and any other class of securities. Each Share of Class F Preferred Stock shall not be convertible at any time. Each Share of Class F Preferred Stock shall be entitled to One Thousand (1,000) votes on any matter on which any of the shareholders are required or permitted to vote. No dividends shall be paid on any Series “F” Preferred Stock.   During the nine months ended September 30, 2024, the Company issued no options under the Company’s 2021 Stock Incentive Plan (the “Plan”).   During the nine months ended September 30, 2024, the Company issued no convertible debt exchangeable into shares of common stock.

v3.24.3

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 – SUBSEQUENT EVENTS   The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q, and has determined that there have been no such events that have occurred that would require reporting or adjustments to our disclosures.

v3.24.3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Interim Financial Statements	Interim Financial Statements   The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim financial statements should be viewed in conjunction with the audited financial statements of the Company for the year ended December 31, 2023.
Use of Estimates	Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could and likely will differ from those estimates.
Intangible asset	Intangible asset   Management has classified the iTDE Technology as an indefinite intangible asset based on it being a fundamental stem technology that has applications in numerous fields and that is anticipated to give rise to other applications and process techniques. This means that several additional patents are expected to be generated over the course of a number of years as the basic technology is adapted to different fields. As a result, the Company has recorded no amortization against the asset which remains at its October 1, 2021, value of $3,150,114 (see Note 5 to these unaudited condensed financial statements and disclosure in the preamble to the present 2024 10-Q). The Company conducts regular assessments of the iTDE Technology to identify if its value is impaired in any way, (i) on an annual basis and (ii) if, in the opinion of Management, there exists any external or internal reason why the asset might be impaired. In the opinion of management, as at the date of this report, there exists no external or internal reason why the asset might be impaired.
Revenue Recognition	Revenue Recognition   The Company utilizes a five-step process when assessing the recognition of revenue from contractual obligations.     (i) Identification of the type and binding nature of the contract as well as an identification and assessment of the goods and services undertaken with specific reference to the intangible nature of the intellectual property rights sold;   (ii) Identification of specific performance obligations within the overall contract that are distinct.   (iii) Determination of the specific price or value of the specific performance obligation.   (iv) Allocation of the transaction price or value of a specific performance obligation; and   (v) Determination of the moment the obligation undertaken is delivered or performance is satisfied.

v3.24.3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	As of September 30, 2024, and December 31, 2023, accounts payable and accrued liabilities consisted of as follows:  SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES     September 30,     December 31       2024     2023   Accounts payable and accrued expenses   $ 905,136     $ 698,009   Accrued payroll     1,931,969       1,668,748   Accrued interest     183,598       76,450   Total   $ 3,020,703     $ 2,443,207
SCHEDULE OF VARIOUS INTEREST PAYMENTS	SCHEDULE OF VARIOUS INTEREST PAYMENTS           Fourth Quarter 2024   $ 250,000   2025   $ 595,000

v3.24.3

GOING CONCERN (Details Narrative) - USD ($) shares in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Subsidiary, Sale of Stock [Line Items]
Accumulated deficit	$ 7,273,354						$ 7,273,354		$ 6,053,963
Net loss	354,495	$ 345,933	$ 518,963	$ 922,857	$ 397,724	$ 457,973	1,219,391	$ 1,778,554
Net cash used in operating activities							1,033,072	$ 366,458
Amount payable to employee	$ 566,250						566,250
Salary remuneration and expenses payables							2,163,254
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Outstanding payables							$ 212,046
Number of shares issued	3						3

v3.24.3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	Oct. 01, 2021 USD ($)
Accounting Policies [Abstract]
Amortization	$ 3,150,114

v3.24.3

PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Prepaid expense and other current asset	$ 591,070		$ 72,925
Prepaid expense	518,145	$ 50,760
Loans receivable	$ 496,025
Interest receivable percentage	10.00%
Rental of Laboratory Facilities [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deposit	$ 1,600
Consultancy Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deposit	$ 600

v3.24.3

PRINCIPAL ASSET (iTDE TECHNOLOGY) (Details Narrative) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Extraction technology, value	$ 3,150,114	$ 3,150,114

v3.24.3

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 905,136	$ 698,009
Accrued payroll	1,931,969	1,668,748
Accrued interest	183,598	76,450
Total	$ 3,020,703	$ 2,443,207

v3.24.3

SCHEDULE OF VARIOUS INTEREST PAYMENTS (Details)	Sep. 30, 2024 USD ($)
Payables and Accruals [Abstract]
Fourth Quarter 2024	$ 250,000
2025	$ 595,000

v3.24.3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative) - USD ($)	Feb. 29, 2024	Sep. 30, 2024
Payables and Accruals [Abstract]
Loans payable		$ 845,000
Indebtedness of employees, description	These agreements set out the terms under which such people would receive their past indebtedness, except for the employee that resigned, their future remuneration. Each of these agreements provides for all the indebtedness due to the respective persons to become due and payable as soon as the Company shall have either (i) achieved an annual EBITDA of $5 million per annum as indicated by reference to the Annual Report of the Company on Form 10-K or if no such report is filed, in accordance with the audited financial reports presented to the shareholders, or, (ii) achieved a quarterly income figure of $12 million, or, (iii) the Board of Directors of the Company shall declare the Indebtedness due. Until such time as payment is made, all Indebtedness shall incur interest at 8%. The Agreements additionally provide for the respective salaries fixed in the employment agreements to be reduced to at least one quarter of the amount of remuneration set forth in the employment or consulting agreement from March 1, 2024. Remuneration will increase to one half of the agreed salary either (a) on the date on which the Company shall raise more than $3 million in equity or debt finance, or (b) the date on which the Company shall receive booked revenue.
Indebtedness and penalty interest conversion, description	(i) the price which is five percent (5%) lower than the average trading price of the five business trading days immediately preceding the date of the election, or (ii), if the Company is in the process of raising finance and has made an offering to the public by reporting the offering to the Securities Exchange Commission (“SEC”), at the price that is five percent (5%) lower than the price recorded in such reported offering provided such offering shall have been active at any time during the previous quarter.
Indebtedness agreement, description	The indebtedness of the Company to the signatories shall be accelerated and become immediately due and payable in the event that the Company shall fail: (i) (a) to achieve an annual EBITDA of $5 million per annum, or, (b) to achieve a quarterly income figure of $12 million, or, (c) to declare the Indebtedness on or before February 28, 2027; or (ii) to pay the monthly remuneration agreed in the agreement within 11 days of the month end in which the remuneration was incurred.

v3.24.3

CONVERTIBLE NOTES, PROMISSARY NOTES AND LOANS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Interest rate	10.00%
Loans payable current	$ 845,000	$ 945,000
17 Series F Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Convertible notes	$ 1,220,004
Interest rate	10.00%
Loans payable current	$ 0
Interest expense	$ 128,351

v3.24.3

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Sep. 30, 2024	Sep. 23, 2024	May 29, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Preferred stock, shares authorized	5,000,000			5,000,000
Series F Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock, shares authorized		20,000
Related Party [Member] | Directors Officers and Employees [Member]
Related Party Transaction [Line Items]
Total amount owed to related party	$ 2,163,254
Related Party [Member] | Five Senior Managers [Member]
Related Party Transaction [Line Items]
Total amount owed to related party	$ 1,988,677
John Michael Johnson [Member] | Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock, shares authorized			10,000
John Michael Johnson [Member] | Series F Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock, shares authorized		10,000

v3.24.3

STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) - USD ($)			9 Months Ended
	Sep. 23, 2024	May 29, 2024	Sep. 30, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized			100,000,000	100,000,000
Common stock, par value			$ 0.001	$ 0.001
Preferred stock, shares authorized			5,000,000	5,000,000
Preferred stock, par value			$ 0.001	$ 0.001
Common stock, shares outstanding			28,546,834	28,546,834
2021 Stock Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Option issued			0
Preferred Class A [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, par value		$ 0.001
Preferred stock, shares authorized		20,000
Conversion of convertible securities		250
Preferred stock, voting		500
Preferred Class A [Member] | John Michael Johnson [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued		10,000
Preferred Class A [Member] | Director [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued		10,000
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued			20,000
Preferred stock conversion, description		Each share of Class A Preferred Stock ranks senior to all Common Stock and any other class of securities that is specifically designated as junior to Class A Preferred Stock. Each Share of Class A Preferred Stock shall be convertible at any time by the holder thereof into 250 shares of Common Stock, however, any Series A Preferred Stock remaining unconverted at 5:00 P.M., Las Vegas, Nevada time on January 1, 2026, shall be automatically converted into Two Hundred Fifty (250) shares of the Company’s Common Stock (par value $0.001). Each Share of Class A Preferred Stock shall be entitled to Five Hundred (500) votes on any matter on which any of the shareholders are required or permitted to vote.
Dividends		$ 0
Series F Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized	20,000
Preferred stock, shares issued			20,000
Preferred stock conversion, description	Each share of Class F Preferred Stock ranks senior to all Common Stock and any other class of securities. Each Share of Class F Preferred Stock shall not be convertible at any time. Each Share of Class F Preferred Stock shall be entitled to One Thousand (1,000) votes on any matter on which any of the shareholders are required or permitted to vote.
Preferred stock, voting	1,000
Dividends	$ 0
Series F Preferred Stock [Member] | John Michael Johnson [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued	10,000
Series F Preferred Stock [Member] | Director [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued	10,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock to shareholders			0
Debt conversion, shares issued			0

---